A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS

NCT04358393 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

69

Enrollment

INDUSTRY

Sponsor class

Conditions

AML
Acute Myeloid Leukemia
Chronic Myelomonocytic Leukemia
CMML
Myelodysplastic Syndromes
High-risk Myelodysplastic Syndrome
MDS

Interventions

DRUG: APG-115
DRUG: 5-azacitidine

Sponsor

Ascentage Pharma Group Inc.